Latest News and Press Releases

Vilobelimab is the first authorized drug to control complement factor C5a, a protein that plays an important and often harmful role in the body's immune responseFDA granted EUA based on Phase III...

Major progress in development of vilobelimab Phase III study in PG announced following detailed feedback and recommendations from the U.S. Food and Drug Administration (FDA); clinical trial protocol...

Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG) Trial size to be adapted upon interim analysis with planned total patient...

InflaRx will provide access to certain clinical, manufacturing and regulatory documentation for vilobelimab to facilitate STS’s regulatory filings in ChinaSTS plans to request regulatory approval in...

Randomized, double-blind, placebo-controlled Phase I trial of orally administered complement inhibitor INF904 initiatedStudy designed as single ascending dose to determine safety, tolerability and...

Vilobelimab earns Orphan Drug and Fast Track designation for the treatment of critically ill, intubated, mechanically ventilated COVID-19 patients - Emergency Use Authorization (EUA) submitted to U.S....

Company also earns FDA Fast Track designation for vilobelimab to treat critically ill COVID-19 patientsEUA submission based on Phase III results in critically ill COVID-19 patients, recently published...

JENA, Germany, Sept. 09, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement...

The Lancet Respiratory Medicine, a peer-reviewed journal, published the results of the PANAMO trial, one of the largest, global, 1:1 randomized, placebo-controlled Phase III studies conducted in...

Fast Track and Orphan Drug designation for vilobelimab in pyoderma gangrenosum (PG) granted by the FDAPlans to submit EUA with the FDA for vilobelimab in critically ill COVID-19 patients...